LAPSE:2023.5338
Published Article
LAPSE:2023.5338
Anti-Cancer Effect of Panax Ginseng and Its Metabolites: From Traditional Medicine to Modern Drug Discovery
Sejin Kim, Nayeon Kim, JaYeon Jeong, Soojin Lee, Woojin Kim, Seong-Gyu Ko, Bonglee Kim
February 23, 2023
Cancer incidence and mortality rate are growing worldwide. The effectiveness of cancer therapy depends on the degree of cancer development. Anticancer prevention, screening tests, detection of precancerous conditions or cancers at an early stage of development help to prevent the development of cancer, and in the event of cancer development, they provide the best chance for a full recovery. However, in most cases of advanced cancer, there is no method that can fully cure this disease. Recently, natural products have gained more attention in cancer therapy. Panax ginseng (PG), one of the most popular natural products, is reported to have a wide range of pharmacological activities in cancer. Therefore, the anti-cancer effects and mechanisms of PG and its metabolites (compound K, Ginsenoside Rh1, Rh2, Rh3 and F1) in five major cancers (lung cancer, breast cancer, colon cancer, prostate cancer and stomach cancer) are reviewed in this study. It is confirmed that PG and its metabolites regulated apoptosis, epithelial mesenchymal transition (EMT), angiogenesis, cell cycle arrest and multidrug resistance (MDR) in vitro and in vivo cancer models. In particular, ginsenoside Rh2 showed anticancer effects in all five major cancers. This review could improve the understanding of anticancer mechanisms of PG and its metabolites against major five cancers. Further clinical studies are needed for development anti-cancer drugs using PG and its metabolites.
Keywords
angiogenesis, apoptosis, cancer, compound K, ginsenoside Rh2, multidrug resistance, Panax ginseng
Subject
Suggested Citation
Kim S, Kim N, Jeong J, Lee S, Kim W, Ko SG, Kim B. Anti-Cancer Effect of Panax Ginseng and Its Metabolites: From Traditional Medicine to Modern Drug Discovery. (2023). LAPSE:2023.5338
Author Affiliations
Kim S: College of Korean Medicine, Kyung Hee University, 1 Hoegi-dong, Dongdaemun-gu, Seoul 05253, Korea [ORCID]
Kim N: College of Korean Medicine, Kyung Hee University, 1 Hoegi-dong, Dongdaemun-gu, Seoul 05253, Korea
Jeong J: College of Korean Medicine, Kyung Hee University, 1 Hoegi-dong, Dongdaemun-gu, Seoul 05253, Korea
Lee S: Department of Clinical Korean Medicine, Graduate School, Kyung Hee University, 1 Hoegi-dong, Dongdaemun-gu, Seoul 05253, Korea
Kim W: Korean Medicine-Based Drug Repositioning Cancer Research Center, College of Korean Medicine, Kyung Hee University, 1 Hoegi-dong, Dongdaemun-gu, Seoul 05253, Korea [ORCID]
Ko SG: Korean Medicine-Based Drug Repositioning Cancer Research Center, College of Korean Medicine, Kyung Hee University, 1 Hoegi-dong, Dongdaemun-gu, Seoul 05253, Korea
Kim B: College of Korean Medicine, Kyung Hee University, 1 Hoegi-dong, Dongdaemun-gu, Seoul 05253, Korea; Korean Medicine-Based Drug Repositioning Cancer Research Center, College of Korean Medicine, Kyung Hee University, 1 Hoegi-dong, Dongdaemun-gu, Seoul 05253, [ORCID]
Journal Name
Processes
Volume
9
Issue
8
First Page
1344
Year
2021
Publication Date
2021-07-30
Published Version
ISSN
2227-9717
Version Comments
Original Submission
Other Meta
PII: pr9081344, Publication Type: Review
Record Map
Published Article

LAPSE:2023.5338
This Record
External Link

doi:10.3390/pr9081344
Publisher Version
Download
Files
[Download 1v1.pdf] (1.5 MB)
Feb 23, 2023
Main Article
License
CC BY 4.0
Meta
Record Statistics
Record Views
76
Version History
[v1] (Original Submission)
Feb 23, 2023
 
Verified by curator on
Feb 23, 2023
This Version Number
v1
Citations
Most Recent
This Version
URL Here
https://psecommunity.org/LAPSE:2023.5338
 
Original Submitter
Auto Uploader for LAPSE
Links to Related Works
Directly Related to This Work
Publisher Version